Y-mabs Therapeutics Stock News

Y-Mabs Therapeutics Inc (YMAB) shares closed today at 0.7% above its 52 week low of $13.94, giving the company a market cap of $612M. The stock is currently down 13.4% year-to-date, down 72.5% over the past 12 months, and down 41.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 4.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 741.5% The company's stock price performance over the past 12 months lags the peer average by 135.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Y-Mabs Therapeutics Inc (YMAB) shares closed 0.2% lower than its previous 52 week low, giving the company a market cap of $660M. The stock is currently down 6.7% year-to-date, down 69.7% over the past 12 months, and down 37.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 23.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 743.0% The company's stock price performance over the past 12 months lags the peer average by 128.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Y-Mabs Therapeutics Inc (YMAB) shares closed today at 1.2% above its 52 week low of $14.95, giving the company a market cap of $660M. The stock is currently down 6.7% year-to-date, down 69.7% over the past 12 months, and down 37.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 21.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -726.5% The company's stock price performance over the past 12 months lags the peer average by 131.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Y-mAbs Therapeutics (NASDAQ:YMAB)s stock had its buy rating reaffirmed by investment analysts at HC Wainwright in a report released on Wednesday, TipRanks reports. They currently have a $68.00 price objective on the stock. HC Wainwrights target price suggests a potential upside of 285.27% from the companys previous close. A number of other analysts also recently [] The post Y-mAbs Therapeutics (NASDAQ:YMAB) Given Buy Rating at HC Wainwright appeared first on ETF Daily News .

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned a consensus recommendation of Buy from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among analysts that have []

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that […]

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that clinical experience for naxitamab and data from the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place virtually today at 12 p.m. Eastern Time.

Brokerages forecast that Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) will post $10.98 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Y-mAbs Therapeutics earnings, with estimates ranging from $9.90 million to $12.83 million. Y-mAbs Therapeutics posted sales of $20.75 million during the same quarter last year, which []

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a virtual research and development day on Wednesday, December 15, 2021 at 12pm Eastern Time.

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) gapped up before the market opened on Friday . The stock had previously closed at $16.04, but opened at $17.50. Y-mAbs Therapeutics shares last traded at $16.92, with a volume of 1,218 shares trading hands. A number of equities analysts have issued reports on the company. Zacks Investment Research []

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has received an average recommendation of Buy from the six analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a []

Y-mAbs Therapeutics (NASDAQ:YMAB) was downgraded by research analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating in a report released on Tuesday, The Fly reports. They currently have a $30.00 target price on the stock, down from their prior target price of $57.00. JPMorgan Chase & Co.s price objective points []

Y-mAbs Therapeutics, Inc.'s (YMAB) CEO Claus Moller on Q3 2021 Results - Earnings Call Transcript

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of no